Navigation Links
Medicure's MEND-CABG Trial Results Published in Peer Reviewed,Journal

WINNIPEG, Manitoba - (May 31, 2007) Medicure Inc. (TSX:MPH; Amex:MCU), a cardiovascular focused biopharmaceutical company, today announced that the results from its Phase 2 MEND-CABG trial are featured in a peer reviewed article in the June edition of The Journal of Thoracic and Cardiovascular Surgery, published by the American Association of Thoracic Surgery.

The article, titled, "Effects of pyridoxal-5-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: Results of the MEND-CABG randomized study", outlines evidence of MC-1's potential efficacy in reducing ischemic reperfusion injury. Additionally, the article presents further detail, background information and analysis of Medicure's positive MEND-CABG study.

"We are pleased that our novel cardioprotective product MC-1 is being recognized by one of the leading cardiovascular surgery journals," stated Medicure's President and CEO, Albert D. Friesen, PhD. "The results from MEND-CABG clearly show that patients treated with MC-1 experienced clinically meaningful reductions in the composite endpoint, driven by a pronounced reduction in large non-fatal myocardial infarctions, which comprise the majority of events after CABG surgery. We eagerly anticipate the results of the ongoing pivotal Phase 3 MEND-CABG II registration trial."

Additional Clinical Data

The article also includes new data from a post-hoc analysis demonstrating a statistically significant lower incidence of atrial fibrillation in the MC-1 groups (250 mg @.7% and 750 mg @.0%) compared to the placebo group (11.9%) between post operative day (POD) four and the end of the trial.

"Atrial fibrillation is one of the most common complications after CABG surgery, and is associated with a significant increase in morbidity and mortality, as well as prolonged hospital stay and increased hospital costs," commented Dr. Friesen. "Prevention of atrial fibrilla
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Medicure MEND CABG Trial Results Published Peer Reviewed Journal
(Date:7/7/2015)... 30, 2015 ... the addition of the "Biomedical Photoacoustic ... offering. This patent landscape focuses ... is a safe, non-invasive, non-ionizing imaging technique. ... a great alternative to traditional medical imaging ...
(Date:7/7/2015)... , July 7, 2015 A power morcellator ... has been settled for an undisclosed amount, Bernstein Liebhard ... filed in March 2014 in the U.S. District Court, ... behalf of a widower whose wife had died in ... a hysterectomy that involved the use of a power ...
(Date:7/7/2015)... California , 7 de julio de 2015 ... médicos de propiedad privada centrada en el desarrollo ... enfermedad neurovascular, ha anunciado hoy que R. ... junta directiva. Kleine cuenta con ... industrias de los dispositivos médicos y la sanidad. ...
Breaking Medicine Technology:Worldwide Biomedical Photoacoustic Imaging Patent Landscape Report 2015 2Worldwide Biomedical Photoacoustic Imaging Patent Landscape Report 2015 3Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 2Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 3Sequent Medical nombra a Mike Kleine a su junta directiva 2Sequent Medical nombra a Mike Kleine a su junta directiva 3
... VILLAGE, Colo., Jan. 5, 2012 Ampio Pharmaceuticals, Inc. (NASDAQ: ... company that discovers and develops new uses for previously approved ... will hold a Web Cast on Thursday, January 26, 2012 ... to update our shareholders on the company,s progress and a ...
... AMRI ), a global contract services organization, announced ... agreement with BioPontis Alliance LLC. The agreement is aimed ... early-stage research and technologies being discovered and developed in ... services in small molecule discovery, development, and manufacturing in ...
Cached Medicine Technology:Ampio Pharmaceuticals Schedules Webcast to Update Shareholders 2Ampio Pharmaceuticals Schedules Webcast to Update Shareholders 3AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC 2AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC 3
(Date:7/7/2015)... Antonio, TX (PRWEB) , ... July 07, 2015 , ... ... has once again teamed up with Soldiers’ Angels and announced a new charity campaign ... is the motivation and mission of Soldiers’ Angels, which was created especially to care ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... and creative design firm, today announced that TimberNook ( http://www.timbernook.com/ ) ... media campaign, content strategy, and marketing launch package for new camp providers. ...
(Date:7/7/2015)... ... July 07, 2015 , ... Bayco’s ... with the introduction of the Nightstick XPP-5422GM , the world’s first Intrinsically ... at its base and one on its clip. The new Nightstick XPP-5422GM is ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... Whole Health (NIWH) have jointly announced a partnership focused on providing knowledge ... medical case studies. The study will be conducted with NIWH trained patient health ...
(Date:7/7/2015)... MD (PRWEB) , ... July 07, 2015 , ... ... and an official accrediting body as designated by the Centers for Medicare and ... user experience and to enhance compatibility with mobile devices. , The most effective ...
Breaking Medicine News(10 mins):Health News:Clear Insurance Group and Nonprofit Soldiers’ Angels Initiate New Charity Campaign in San Antonio, TX to Provide Aid and Comfort for Veterans 2Health News:Clear Insurance Group and Nonprofit Soldiers’ Angels Initiate New Charity Campaign in San Antonio, TX to Provide Aid and Comfort for Veterans 3Health News:TimberNook Selects Calypso Communications for PR, Social Media and Content Strategy 2Health News:Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight 2Health News:Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight 3Health News:Isabel Healthcare and the National Institute of Whole Health Announce Partnership for a Pilot Study Using the Isabel Diagnostic Support Tool and Knowledge Organizer 2Health News:Isabel Healthcare and the National Institute of Whole Health Announce Partnership for a Pilot Study Using the Isabel Diagnostic Support Tool and Knowledge Organizer 3Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 3
... these factors influence how likely they are to ... Racial and ethnic variations in how women perceive their ... get screened for cancer, particularly colon cancer, says a ... researchers interviewed 1,160 women, ages 50 to 80, about ...
... In Time For Summer, CINCINNATI, April 15 ... Americans beautify their insides this summer,with the addition of ... lineup. Pink Lemonade joins Berry Burst and Orange flavors ... 100 percent,fiber from psyllium husk making it a delicious ...
... 15 Gentiva Health,Services, Inc. (Nasdaq: GTIV ), ... services, today announced that it has,scheduled a conference call ... 10:00,a.m. ET to discuss operating results for the first ... financial news release the morning of May,1 before pre-market ...
... OF APPROXIMATELY $3.10-$3.20 PER ... DILUTED SHARE, NEW ... pharmaceutical company, today announced that,fully diluted earnings per share (EPS) for the ... share include a,charge of $110,138,000, or $0.35 per share net of tax, ...
... cancer drug Sutent may slow liver cancer progression, scientists ... A new drug duo might help prevent colorectal cancer, ... the progression of liver cancer. , So conclude two ... Research annual meeting in San Diego. , In the ...
... April 15 Wellcorps International, one of,the nations ... a major paper on the history and evolution ... can be found in its entirety at, http://www.wellcorps.com ... Tony Rich and noted,clinical medical anthropologist Meg Jordan, ...
Cached Medicine News:Health News:Women's Awareness of Cancer Risk Linked to Race, Ethnicity 2Health News:Quench Your Summer Thirst...With Fiber 2Health News:Quench Your Summer Thirst...With Fiber 3Health News:Gentiva(R) Health Services Schedules First Quarter Earnings Call and Web Cast for Thursday, May 1, 2008 2Health News:Gentiva(R) Health Services Schedules First Quarter Earnings Call and Web Cast for Thursday, May 1, 2008 3Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 2Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 3Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 4Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 5Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 6Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 7Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 8Health News:Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment 9Health News:New Drug Duo Helps Fight Colon Cancer 2Health News:New Drug Duo Helps Fight Colon Cancer 3Health News:New Drug Duo Helps Fight Colon Cancer 4Health News:Wellcorps International Releases Major Paper on History and Evolution of Amphetamine and Anti-Depressant Use in America 2
... This new microplate reader for ... with an emphasis on superior performance ... as sensitive glow luminescence measurements. Synergy ... 3 mm top, 5 mm bottom ...
Diareader ELX800G...
EL301 Microwell Strip Reader is a portable, rugged, single/dual wavelength photometer designed to measure and interpret the absorbances of microwell strip assays....
Elisa strip reader...
Medicine Products: